What are your top takeaways from ASCO GU 2024?

1. Prostate. BRCAAway. This small but important phase 2 randomized multicenter trial of HRRm mCRPC in the first line setting demonstrated the clear synergy in delaying progression or death and inducing better response between abiraterone and olaparib as compared to either abi or olaparib monotherapy or sequential therapy. This trial of about 60 patients essentially confirms the PROPEL data, which led to the FDA approval in 2023 for BRCAm mCRPC (see Saad et al., PMID 37714168) and the EU/EMEA broad...

GETUG 18 is an RCT for high-risk PCa receiving LT-ADT for 3 years and 70 Gy vs 80 Gy with conventional fractionation. All patients had nodal RT (unless had PLND). The 10-year PFS was 83.6% vs 72.2%. The 10-year OS was 77% vs 65.9%. There was no difference in morbidity between the two arms but appears there was more use of IMRT and IGRT in the 80 Gy arm.

The previous studies of dose escalation have also shown improvement in BCR, PFS, and DM. This is the first one to show improvement in OS with a...

1. AMBASSADOR Alliance A031501 trial provides additional evidence to support a DFS benefit with adjuvant immune checkpoint inhibition (pembrolizumab) in patients with muscle-invasive and locally advanced urothelial carcinoma. NCT03244384
2. Although CONTACT-02 demonstrated a PFS benefit for cabozantinib plus atezolizumab versus a second novel hormonal agent in patients with mCRPC, the control arm and absence of a cabozantinib monotherapy arm confounds the findings, particularly so in the absence of a...

1. Results of the AMBASSADOR study for adjuvant pembrolizumab therapy for urothelial cancer
2. Further analysis of the EMBARK study
3. OS results from KEYNOTE-564 of adjuvant pembrolizumab in clear cell RCC